Memorial Sloan-Kettering Cancer Center cell engineering researchers and their clinician colleagues have been in the news recently for a successful experimental cell therapy. Called targeted immunotherapy, a patient's T cells are genetically altered in the lab, then reintroduced with the directive to target and kill cancer cells. The treatment was carried out on a group of adults who all suffered from a rapidly progressing form of leukemia that had not responded to chemotherapy. All five went into remission after the novel cell treatment, and three have stayed that way for a number of months. Results of the ongoing clinical trial appeared in the March 20 online edition of the journal Science Translational Medicine, along with an article in the New York Times.
Science Market Update
Tags: 2014, Rockefeller University, 2013, Northeast, Leukemia, immunotherapy, cancer research, New York, Memorial Sloan-Kettering Cancer Center, Cancer Treatment, Immune System, Cell Research, RockU, BioResearch Product Faire Event, NY, New York City, MSKCC
The Knight Cancer Institute at Oregon Health & Science University (OHSU) in Portland has just announced an important partnership with San Diego-based bioprinting technology company Organovo. Research into the biology of cancer, especially how it metastasizes, has been complicated in the past by the limitations of animal models and cell cultures, which really don't tell us enough about the workings of cancer within a human being. Organovo creates living, 3-D human tissue using their bioprinting device, the NovoGen MMX (below). The partnership between OHSU and Organovo will allow cancer research at Knight Institute labs to much more closely model the complex architecture of malignancy within the human body, using in vitro tissue. Ultimately this will lead to the development of more accurate therapeutics and pre-clinical trials.
Tags: 2014, 2013, Oregon Health Sciences University, Oregon Health and Science University, Northwest, cancer research, Oregon, Cancer Treatment, bioprinting, BioResearch Product Faire Event, Funding, Front Line event, OR, OHSU, Portland, Northwest Region
Often growing up as a child you hear, “eat your veggies if you want to grow up to be big and strong.” With new research on triple negative breast cancer, that old saying might have to change to "eat your veggies if you want to keep cancer away". Recently, at the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, Mandip Sachdeva announced: "We are confident that the compounds we are currently working with are an effective treatment for triple-negative breast cancer. These compounds are safer for the patient than current treatments available".
Tags: Bioscience research, cancer research, Texas A&M University, Texas, 2012, Cancer Treatment, Cancer, College Station, BioResearch Product Faire Event, Texas A&M Research, Texas A&M Life Science Funding, TX, Texas A&M
Cancer research is hot, and the best in the field are hotly-courted by top cancer research centers, often with very attractive compensation packages in addition to state-of-the-art labs and equipment. As if fighting cancer weren't challenging enough, even renowned universities with world-class biomedical programs like the University of California San Diego have had some of their shining stars in the laboratory snatched away by big-money states like Texas in recent years. Not to be outdone or undermined, UCSD has recently engaged in some aggressive recruiting of its own and is proud to announce that two very important players in the cancer research field have joined the Moores Cancer Center faculty: Dr. Napoleone Ferrara (formerly of Genentech) and Dr. Razelle Kurzrock (formerly of MD Anderson at the University of Texas).
ARCHITECT'S RENDERING OF NEW PROTON BEAM THERAPY FACILITY IN ROCHESTER, MINN.(Courtesy of mayoclinic.org)